NervGen Pharma Corp. (NGEN)
1.43
+0.01
(+0.70%)
USD |
NASDAQ |
Oct 23, 16:00
1.42
-0.01
(-0.70%)
After-Hours: 20:00
NervGen Pharma Enterprise Value : 91.00M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 91.00M |
| October 22, 2026 | 89.93M |
| October 21, 2026 | 98.45M |
| October 20, 2026 | 102.70M |
| October 19, 2026 | 102.70M |
| October 16, 2026 | 108.02M |
| October 15, 2026 | 111.22M |
| October 14, 2026 | 105.36M |
| October 13, 2026 | 112.28M |
| October 12, 2026 | 122.92M |
| October 09, 2026 | 122.92M |
| October 08, 2026 | 125.05M |
| October 07, 2026 | 123.98M |
| October 06, 2026 | 125.05M |
| October 05, 2026 | 131.43M |
| October 02, 2026 | 128.24M |
| October 01, 2026 | 126.11M |
| September 30, 2026 | 142.07M |
| September 29, 2026 | 143.14M |
| September 28, 2026 | 138.88M |
| September 25, 2026 | 145.27M |
| September 24, 2026 | 153.78M |
| September 23, 2026 | 147.40M |
| September 22, 2026 | 158.57M |
| September 21, 2026 | 150.59M |
| Date | Value |
|---|---|
| September 18, 2026 | 156.97M |
| September 17, 2026 | 180.38M |
| September 16, 2026 | 165.49M |
| September 15, 2026 | 166.55M |
| September 14, 2026 | 172.40M |
| September 11, 2026 | 171.34M |
| September 10, 2026 | 168.68M |
| September 09, 2026 | 165.49M |
| September 08, 2026 | 171.87M |
| September 04, 2026 | 186.77M |
| September 03, 2026 | 185.70M |
| September 02, 2026 | 186.77M |
| September 01, 2026 | 185.70M |
| August 31, 2026 | 174.00M |
| August 28, 2026 | 181.45M |
| August 27, 2026 | 187.30M |
| August 26, 2026 | 174.00M |
| August 25, 2026 | 160.16M |
| August 24, 2026 | 151.65M |
| August 21, 2026 | 136.75M |
| August 20, 2026 | 126.11M |
| August 19, 2026 | 125.05M |
| August 18, 2026 | 120.79M |
| August 17, 2026 | 117.60M |
| August 14, 2026 | 123.45M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| InMed Pharmaceuticals, Inc. | 5.455M |
| Milestone Pharmaceuticals, Inc. | 51.92M |
| Appili Therapeutics, Inc. | 10.20M |
| Clearmind Medicine, Inc. | -1.539M |
| Lexaria Bioscience Corp. | 1.165M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 7.803M |
| Total Expenses (Quarterly) | -7.803M |
| EPS Diluted (Quarterly) | -0.0925 |
| Earnings Yield | -27.98% |
| Normalized Earnings Yield | -29.09 |